People · Operator
Named in public records as an officer, director or promoter · active 2016–2016 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ViewPoint Therapeutics, Inc. | — | Biotechnology | Series B | $24.9M | $830.9M | 2016 |
Jason E. Gestwicki at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jason E. Gestwicki on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ed Hurwitz | 1 | 9 |
| Peter T. Moldt | 1 | 2 |
| Douglas T. Crawford | 1 | 1 |
| Leah Makley | 1 | 1 |
| Heath T. Lukatch | 1 | 1 |
| Mark T. Blumenkranz, M.D. | 1 | 1 |
| Emmett T. Cunningham, Jr. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.